Skip to content

Influencing the activity of somatic comorbidities through trauma-centered psychotherapy with EMDR using autoimmune thyroiditis Hashimoto as an example

Influencing the activity of somatic comorbidities through trauma-centered psychotherapy with EMDR using autoimmune thyroiditis Hashimoto as an example

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00030624
Enrollment
32
Registered
2022-12-09
Start date
2023-01-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimotos Thyreroditis F43.1

Interventions

Group 1: single-arm, not blinded. Retrospectively, data on diagnosis confirmation, as well as medication schedules for the required substitution dose will be evaluated as a measure of autoimmune and i

Sponsors

Praxis für EMDR
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: PTSD and comorbidity autoimmune thyroiditis Hashimoto's disease

Exclusion criteria

Exclusion criteria: Age under 18, age over 65

Design outcomes

Primary

MeasureTime frame
in parallel with trauma-focused treatment with EMDR with integration of traumatic memory and regulation of emotional stress, is the autoimmune activity of Hashimoto's autoimmune thyroiditis comorbidity reduced? The substitution dose (thyroid hormone substitution with medication) serves as the measurement parameter. This parameter is checked before the start of trauma-centered psychotherapy with EMDR, during, at the end of, and three months after the end of therapy using the medication schedule.

Secondary

MeasureTime frame
correlates autoimmune activity measured by substitution dose at the conclusion of trauma-centered psychotherapy with parameters for traumatic stress measured by the IES-R (Impact of Event Scale-Revised).

Countries

Austria, Germany

Contacts

Public ContactClaas Oppermann

Praxis für EMDR

praxis@dr-oppermann-schmid.de0941-28046661

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026